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When low density lipoprotein (LDL) was incubated with sonicated macrophages at acidic pH, its protein moiety was partially degraded by cathep- 
sins B and D. The reisolated LDL was taken up by intact macrophages up to about 20 times as fast as control LDL. LDL proteolysis and its 
enhanced uptake could be inhibited almost entirely by the selective protease inhibitors leupeptin and pepstatin. If macrophages in atherosclerotic 
lesions were to release acidic proteases (either by exocytosis or following cell death) and these were to modify LDL, this may help to explain why 
so much cholesteryl ester accumulates in these cells. 
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1. INTRODUCTION 
Large-scale cholesteryl ester accumulation within 
macrophages is a prominent feature of atherosclerotic 
lesions. This is believed to be derived from low density 
lipoproteins (LDL) in humans, but macrophages take 
up normal LDL only slowly. LDL oxidised by arterial 
endothelial [l] or smooth muscle cells [2] or by macro- 
phages [3,4], however, is taken up more rapidly by 
macrophages by their scavenger eceptors [5]. We re- 
port here another modification of LDL that can greatly 
increase its uptake by macrophages. When the protein 
moiety of LDL, apolipoprotein B-100, was partially 
degraded by acidic proteases from macrophages, the 
LDL was taken up by intact macrophages much faster 
than control LDL. 
2. MATERIALS AND METHODS 
Mouse resident peritoneal macrophages were isolated from female 
T.O. mice, 20-25 g, and cultured overnight [6]. They were washed 3 
times and scraped off the dishes with a ‘rubber policeman’ in 300 mM 
sucrose/l mM Tris/l mM NaaEDTA/gentamicin (50rg/ml) (pH 7.4) 
and sonicated for 15 s [6]. The protein content of the sonicate was 
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determined (71 and it was diluted to 2OOcg protein/ml with the above 
buffer. 
This was incubated at 37°C for 4-48 h with an equal volume of 12’1- 
labelled LDL (200 gg protein/ml) in 200 mM sodium acetate buffer, 
pH 4.5, containing 1 mM NazEDTA and 5 mM dithiothreitol. The 
LDL (1.019-l .063 g/ml) was isolated from normal human blood and 
radioiodinated [6] and discarded after about 1 month. For the con- 
trol, ‘“51-labelled LDL was incubated with the appropriate buffers 
without the sonicate. At the end of the incubation, small samples were 
taken for the determination of the noniodide trichloroacetic acid- 
soluble degradation products [6]. 
The LDL was reisolated by adjusting its density to 1.1 g/ml with 
solid KBr [S] and centrifuging it at 108OOOxg, for 18 h at 10°C. It 
was removed from the top of the tube and dialysed against several 
changes of 154 mM NaCY16.7 mM NaHrP04121.1 mM 
NaaHP041100 /rM NaaEDTA (pH 7.4). Its protein content and 
radioactivity were determined. 
The LDL was incubated for 24 h at 2Ocg protein/ml (unless other- 
wise specified) with intact macrophages plated at lo6 peritoneal cells 
per 22.6 mm well (Costar) or with cell-free wells. The culture medium 
(500~1 per well) was Dulbecco’s modified Eagle’s medium containing 
foetal calf serum (lo%, v/v) and gentamicin (50 /rg/ml) [6]. The 
noniodide acid-soluble degradation products appearing in the 
medium were determined and expressed per mg of cell protein [4]. The 
determined specific activities of the reisolated ‘251-labelled LDL were 
used to calculate their rate of degradation by the intact macrophages. 
The protease inhibitors pepstatin A and Ieupeptin were obtained 
from Sigma. 
3. RESULTS 
Mouse resident peritoneal macrophages in culture 
were sonicated and incubated at pH 4.5 for 4 or 24 h 
with human 12SI-labelled LDL. The LDL was then 
reisolated by ultracentrifugation and incubated with in- 
tact macrophages and its degradation by them meas- 
ured as an estimate of its rate of uptake [9] (Fig. 1). 
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Fig. 1. Increased uptake of proteolysed LDL by macrophages. ‘251-Labelled LDL was incubated with a macrophage sonicate at pH 4.5, reisolated 
and its rate of degradation by intact macrophages determined as a measure of its rate of uptake. The mean f SE for 4 wells of cells is shown. 
*P<O.OOl compared to the relevant control (r-test). 
There was a large increase in the rate of degradation of 
the partially proteolysed LDL by the intact macro- 
phages and this depended on the time of incubation 
with the macrophage sonicate and therefore on its ex- 
tent of proteolysis. The specific activity of the LDL 
declined progressively during its incubation with the 
sonicate, presumably due to the loss from the LDL par- 
ticles of peptide fragments with a relatively high specific 
activity. 
The proteolysis of LDL in the sonicates and its in- 
creased uptake by macrophages could be inhibited to a 
large extent by adding the protease inhibitors leupeptin 
and pepstatin A to the sonicate (Table I). It should be 
noted that EDTA was present during both the incuba- 
tion of the LDL with the sonicates and its reisolation 
and this should have reduced any oxidation of the LDL 
[4,101. 
Untreated 12sI-labelled LDL was added to the buffer 
Table I 
Effect of protease inhibitors on the modification of LDL by macrophage sonicates 
Incubation mixture at pH 4.5 % proteolysis Specific activity Degradation of reisolated 
Macrophage 
of ‘*sI-labelled of ‘251-labelled 
sonicate 
Leupeptin plus LDL at pH 4.5 
‘251-labelled LDL by in- 
pepstatin 
LDL (cpm/ng tact macrophages @g pro- 
protein) tein/mg cell protein in 24 h) 
- 0.26 7.46 6.41 f 0.04 
+ - 12.8 6.05 17.9 + 0.35 
+ 0.16 7.52 4.24 zt 0.09 P<O.OOl 
+ + 0.74 6.82 6.79 f 0.19 
I 
‘*‘I-labelled LDL was incubated for 24 h at 37°C with buffer or a macrophage sonicate, with or 
without leupeptin (35 ,uM) plus pepstatin A (5 ,uM). It was then reisolated and added to intact 
macrophages and its rate of degradation by them determined. The mean f SE for 3 wells of 
macrophages i shown. There was a significant difference between the values indicated as assessed 
by t-test. In another experiment, not shown here, proteolysed LDL produced by 48 h incubation 
with a macrophage sonicate was degraded by intact macrophages 21 times as fast as control LDL. 
This increased egradation by intact macrophages was reduced by about 90% by adding leupeptin 
and pepstatin to the sonicates. 
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of pH 4.5 or to the macrophage sonicate in buffer, 
either with or without leupeptin plus pepstatin, and 
then immediately reisolated by ultracentrifugation 
followed by dialysis. The degradation of this reisolated 
LDL by intact macrophages was similar to that of 
native LDL. Another control that was carried out con- 
sisted of incubating at 37°C a macrophage sonicate in 
buffer of pH 4.5, in the absence of LDL, and then put- 
ting it through the reisolation procedure for LDL. The 
‘phantom’ LDL fraction that was obtained did not af- 
fect the rate of degradation of native r2%labelled LDL 
by intact macrophages. 
The degradation of proteolysed LDL by the intact 
cells was directly proportional to its concentration up to 
at least 50 ,ug protein/ml, the highest concentration 
tested (Fig. 2). The scavenger eceptor did not appear 
to be involved in its uptake, as the degradation by intact 
macrophages of proteolysed ‘251-labelled LDL at 2.5 pg 
protein/ml was not reduced significantly by a large ex- 
cess of nonlabelled acetylated LDL (1OOgg protein/ml). 
The same batch of nonlabelled acetylated LDL, 
however, decreased the degradation of acetylated r2?- 
labelled LDL by about 90% (data not shown). A large 
excess of nonlabelled native LDL also did not compete 
for the degradation by intact macrophages of proteolys- 
ed 1251-labelled LDL. 
Proteolysed LDL was degraded by intact cultured 
smooth muscle cells from pig aortas [l l] somewhat 
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Fig. 2. Effect of proteolysed LDL concentration on its uptake by in- 
tact macrophages. “~1-Labelled LDL was incubated for 48 h with (0) 
or without (0) a macrophage sonicate. After the incubation, 8.36% 
and 0.59%, respectively, of the radioactivity was present in a 
noniodide acid-soluble form. These LDLs were then reisolated and 
together with native (nonincubated) LDL (A) incubated for 24 h at 
various concentrations with intact macrophages and their rates of 
degradation determined. Each point is the mean f SE for 3 wells of 
cells. Similar results were obtained in a separate xperiment. 
faster than control LDL but its rate of degradation per 
mg of cell protein was much less than that for the 
macrophages (results not shown). 
4. DISCUSSION 
We have shown that acidic proteases from macro- 
phages can modify LDL so that intact macrophages will 
take it up much faster. The increased uptake of LDL 
was due to its modification by proteases, as its pro- 
teolysis in the sonicates and its increased uptake by 
macrophages could be almost entirely prevented by the 
protease inhibitors Ieupeptin and pepstatin. This agrees 
with our previous finding that these two inhibitors 
together almost entirely inhibit LDL proteolysis by 
macrophage sonicates [6], presumably due to the inhibi- 
tion of lysosomal cathepsin B by leupeptin and cathep- 
sin D by pepstatin. 
The uptake of proteolysed LDL by intact macro- 
phages did not show any evidence of saturation, at least 
up to 50 pg of protein/ml, the highest concentration 
tested. Macrophages contain active scavenger recep- 
tors, which have very recently been cloned and sequenc- 
ed [5] and which recognise various ligands including ox- 
idised LDL and acetylated LDL. These do not, 
however, appear to be involved in the uptake of pro- 
teolysed LDL as the degradation of labelled proteolysed 
LDL by intact macrophages was not competed for 
significantly by a large excess of nonlabelled acetylated 
LDL. The reason for the increased uptake of proteolys- 
ed LDL by macrophages is therefore unknown. 
Previous studies have shown that LDL can be acted 
upon by pepsin to increase its uptake by mouse 
peritoneal macrophages [121 and trypsin-treated LDL 
has been shown to stimulate cholesteryl ester synthesis 
in these cells more than native LDL [13]. LDL treated 
with trypsin is taken up faster by fibroblasts deficient in 
LDL receptors 1141 and binds more to heparin [15] and 
aortic glycosaminoglycans [ 161. Mast cell granules have 
been shown to contain two neutral proteases, chymase 
and carboxypeptidase A, which partially degrade 
apolipoprotein B-100 and increase its binding to the 
granules [17]. When the granules are phagocytosed by 
macrophages, this leads to the increased uptake of LDL 
by these cells. Polymorphonuclear leukocytes release 
elastase which can partially degrade LDL, cause it to 
form dimers and increase its rate of uptake by human 
monocyte-derived macrophages by their LDL receptors 
1181. In addition, mouse peritoneal macrophages have 
been shown to modify &migrating very low density 
lipoproteins so that they induce increased cholesteryl 
ester accumulation in arterial smooth muscle cells, 
possibly by secreting a serine protease that acts on these 
lipoproteins [ 191. 
The results presented here raise the possibility that 
LDL partially degraded by acidic proteases from 
macrophages in atherosclerotic lesions may be taken up 
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more rapidly in macrophages and contribute to their 
conversion into cholesterol-laden foam cells. The 
lysosomal proteases could either be exocytosed by the 
macrophages or released into the extracellular space 
when the macrophages die and lyse, which is common 
in the more advanced lesions. The lysosomal proteases 
would only be active at an acidic pH but atherosclerotic 
lesions may well be somewhat acidic as they are 
analogous in some ways to chronic inflammation and 
the pH is low in inflammatory sites [20]. In the deeper 
layers of larger lesions the cells may be in a somewhat 
hypoxic environment [21] and may release lactic acid. 
Also the pH near the surface of activated macrophages 
can drop to as low as 3.6 [22]. Another possibility is 
that LDL may be internalised by macrophages and 
delivered to the lysosomes or to an acidic prelysosomal 
compartment containing cathepsins [23], be partially 
degraded there and then released from the cells back in- 
to the extracellular space. 
Thus it is possible that LDL may be modified locally 
in atherosclerotic lesions not only by oxidation but also 
by partial proteolysis by macrophage proteases o that 
it is taken up faster by macrophages. 
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